Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Find insight on Innovent Biologics, Fisher & Paykel Healthcare and more in the latest Market Talks covering Health Care.

Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc ...